Business ❯ Pharmaceuticals

Clinical Trials

Drug Development Product Development Blarcamesine Drug Approval Veterinary Pharmaceuticals Regulatory Affairs Oncology Experimental Drug Investigational Drugs Phase 3 Studies Cardiovascular Drugs Vaccine Development Phase I/II Studies Early Stage Trials

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

Bayer Stroke Drug Asundexian Hits Phase III Goals, Shares Jump